Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Hassan B. Alkhateeb; Razan Mohty; Patricia T. Greipp; Radhika Bansal; Matthew Hathcock; Allison Rosenthal; Hemant S. Murthy; Mohamed A. Kharfan‐Dabaja; José C. Villasboas; N. Nora Bennani; Stephen M. Ansell; Mrinal M. Patnaik; Mark R. Litzow; Rong He; Dong Chen; Aref Al‐Kali; Saad S. Kenderian; Yi Lin; Mithun Vinod Shah

doi:10.1038/s41408-022-00707-4

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Chimeric antigen receptor T-cell therapy (CAR-T) is a novel class of therapeutics with expanding indications. Currently, CAR-T is FDA approved for relapsed, refractory B-cell acute lymphoblastic leukemia, various subtypes of non-Hodgkin lymphoma (NHL), and multiple myeloma [ 1 ].

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alkhateeb et al. (2022) studied this question.

synapsesocial.com/papers/6a7b9b5fd27879525375da81 https://doi.org/10.1038/s41408-022-00707-4

View Full Paper

Ask AI

Bookmark

Share

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Ask about this paper

Abstract

Discussion

Cite This Study

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading